“MEDEZE” Reinforces Its Role as Thailand’s Leading Stem Cell Bank, Reports Soaring Profit in Q1/2025
Dr. Veerapol Khemarangsan Chief Executive Officer of MEDEZE Group Public Company Limited (“MEDEZE”), together with Mr. Phiphat Pitsanuwongrak, Chief Accounting and Finance Officer of MEDEZE Treasury PTE. LTD., provided key business updates to analysts during the Q1/2025 Analyst Meeting, held in a hybrid format at MEDEZE’s headquarters on Phutthamonthon Sai 4.
The company emphasized the ongoing strength and growth of its core businesses in stem cell banking and immune cell (NK cell) services. In the first quarter of 2025, MEDEZE reported total revenue exceeding THB 220 million, marking a 12% year-over-year increase. The company also achieved a robust gross profit margin of 78.05% and a net profit margin of 34.70%, reflecting effective cost management and sustainable business operations.
The leadership further highlighted MEDEZE’s active participation in the “ATMPs Sandbox” initiative, in collaboration with the Department of Disease Control, Ministry of Public Health, aimed at advancing the research and development of Advanced Therapy Medicinal Products (ATMPs) to enhance public health and elevate Thailand as a regional hub for medical innovation in ASEAN.
MEDEZE reaffirmed its commitment to innovation and leadership in the analysis, isolation, cultivation, and cryopreservation of stem cells, as well as NK cell potency testing. These efforts underscore the company’s mission to strengthen investor confidence while contributing to a more sustainable and resilient healthcare system both nationally and regionally.
IR Press Releases